Education
About Us
Working with TipRanks
Follow Us
Ardelyx (ARDX)
NASDAQ:ARDX
ARDX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.21 - $6.78
Previous CloseN/A
Volume1.36M
Average Volume (3M)3.07M
Market Cap
$1.25B
Enterprise Value$908.71M
Total Cash (Recent Filing)$238.45M
Total Debt (Recent Filing)$206.64M
Price to Earnings (P/E)―
Beta0.88
Next Earnings
Oct 30, 2025EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding240,982,830
10 Day Avg. Volume3,093,922
30 Day Avg. Volume3,072,921
Financial Highlights & Ratios
PEG Ratio0.70
Price to Book (P/B)6.88
Price to Sales (P/S)3.57
P/FCF Ratio-26.03
Enterprise Value/Market Cap0.73
Enterprise Value/Revenue2.35
Enterprise Value/Gross Profit2.76
Enterprise Value/Ebitda-28.30
Forecast
1Y Price Target
$11.78Price Target Upside127.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Bulls Say, Bears Say
Bulls Say
Guidance IncreaseManagement's confidence in Ibsrela's trajectory led to the raised 2025 guidance.
Market OpportunityUp to 50% of patients with IBS-C fail GCC agonists, presenting a significant opportunity for Ibsrela due to the lack of effective second-line options.
Revenue GrowthArdelyx delivered a top-line beat with total revenue driven by strong Ibsrela performance and solid Xphozah execution.
Bears Say
Medicare CoverageMedicare Part D no longer covers XPHOZAH and oral phosphate binders from January 1, 2025.
Regulatory ChallengesARDX is arguing CMS does not have the authority to redefine Congress' definition of 'renal dialysis services' and Xphozah should not be included in that definition.
Revenue RetracementA small sequential retracement in overall Xphozah revenue is expected from the first quarter to the second quarter, with growth likely returning in the third quarter.
Ardelyx News
ARDX FAQ
What was Ardelyx’s price range in the past 12 months?
Ardelyx lowest stock price was $3.21 and its highest was $6.78 in the past 12 months.
What is Ardelyx’s market cap?
Ardelyx’s market cap is $1.25B.
When is Ardelyx’s upcoming earnings report date?
Ardelyx’s upcoming earnings report date is Oct 30, 2025 which is in 21 days.
How were Ardelyx’s earnings last quarter?
Ardelyx released its earnings results on Aug 04, 2025. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.132 by $0.052.
Is Ardelyx overvalued?
According to Wall Street analysts Ardelyx’s price is currently Undervalued.
Does Ardelyx pay dividends?
Ardelyx does not currently pay dividends.
What is Ardelyx’s EPS estimate?
Ardelyx’s EPS estimate is -0.06.
How many shares outstanding does Ardelyx have?
Ardelyx has 240,982,830 shares outstanding.
What happened to Ardelyx’s price movement after its last earnings report?
Ardelyx reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.132. Following the earnings report the stock price went up 16.856%.
Which hedge fund is a major shareholder of Ardelyx?
Currently, no hedge funds are holding shares in ARDX
Ardelyx Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.78 (127.85% Upside)
$11.78 (127.85% Upside)
Blogger Sentiment
Bullish
ARDX Sentiment 66%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 920.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $996.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 1.7%
Last 30 Days ▲ 1.1%
Last 30 Days ▲ 1.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-15.66%
12-Months-Change
Fundamentals
Return on Equity
-39.36%
Trailing 12-Months
Asset Growth
35.89%
Trailing 12-Months
Company Description
Ardelyx
Ardelyx, Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with gastrointestinal and renal diseases. The company operates primarily in the biotechnology sector and is known for its lead product, tenapanor, which is designed to treat conditions such as irritable bowel syndrome with constipation (IBS-C) and hyperphosphatemia in patients with chronic kidney disease on dialysis. Ardelyx is committed to addressing unmet medical needs through its proprietary platform that targets the gut and kidneys.
ARDX Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected positive momentum with strong revenue growth, particularly for IBSRELA and XPHOZAH, despite some challenges such as the net loss and the departure of the CFO. The company appears well-positioned for continued growth.View all ARDX earnings summariesARDX Stock 12 Month Forecast
Average Price Target
$11.78
▲(127.85% Upside)
Technical Analysis
Vericel
―
Viridian Therapeutics
―
Dianthus Therapeutics
―
Pharvaris
―
Edgewise Therapeutics
―
Ownership Overview
3.36% Insiders
20.28% Mutual Funds
6.49% Other Institutional Investors
57.98% Public Companies and Individual Investors